Feed QURE
QU

uniQure

QURE · NASDAQ

$44.51 -0.96% (-$0.43)
1M -7.21%
Market Cap $3.09B
P/E Ratio -
Div. Yield -
ROE 111.96%
Piotroski F-Score Weak
3/9
Valuation
0 /100
Expensive
P/B 9.53x
P/S 165.35x
P/FFO N/A
Growth
0 /100
Declining
Book val. growth 25.24%
Rev. growth 46.73%
FCF growth N/A
Profitability
7 /100
Weak
Op. margin 1,089.06%
Gross margin 22.79%
FCF margin 862.32%
Quality
0 /100
Poor
ROA 25.60%
ROIC 23.12%
Asset turnover 0.02x
Debt
69 /100
Low
Int. coverage -3.28x
Debt/Equity 0.19x
Current ratio 10.01x
Stability
25 /100
Unstable
EPS volatility 95.63%
Beta 0.94x
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o QURE
Online

O podjetju

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Matthew C. Kapusta

Employees

221

Headquarters

Amsterdam

Prihajajoči dogodki

09 NOV.

Earnings

Upcoming earnings report

56d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.